Proposed indication: adults with moderately to severely active ulcerative colitis
Population of the pivotal ABTECT trials: inadequate response to conventional or advanced therapy
Indication targeted by the EU paediatric investigation plan
Crohn's disease in development: phase 2b ENHANCE-CD, induction topline results expected mid-2027
ENHANCE-CD induction results timing, January to May 2026, superseded in June 2026